Results 1 to 10 of about 8,937 (172)

Chlorambucil Monotherapy in Dogs with Protein-Losing Nephropathy of Probable Immune Origin: A Preliminary Study [PDF]

Veterinary Sciences
Protein-losing nephropathy (PLN) involves a heterogeneous group of pathologies leading to selective glomerular damage and development of renal disease. ICGN, the main cause of PLN, requires immunosuppressive treatment. However, the scientific evidence in
Felipe Díaz-Soler, María José Bernal, Franco Gonzalez, Ismael Pereira, Francisco Abusleme, Daniela Siel   +5 more
doaj   +2 more sources

Chlorambucil combination therapy in refractory serpiginous choroiditis: A cure?

American Journal of Ophthalmology Case Reports, 2021
Purpose: To find a remedy for serpiginous choroiditis refractory to oral prednisone and chlorambucil treatment. Observations: Eight eyes of four patients (all female) with advanced macular involvement secondary to serpiginous choroiditis were included in
Arash Maleki, Anapatricia Maldonado Cerda, Cristina M. Garcia, Mike Zein, Ambika Manhapra, C. Stephen Foster   +5 more
doaj   +1 more source

In vitro effect of chlorambucil on human glioma cell lines (SF767 and U87-MG), and human microvascular endothelial cell (HMVEC) and endothelial progenitor cells (ECFCs), in the context of plasma chlorambucil concentrations in tumor-bearing dogs. [PDF]

PLoS ONE, 2018
The objective of this study was to investigate a possible mechanism of action of metronomic chlorambucil on glioma by studying the in vitro cytotoxicity and anti-angiogenic effects on glioma and endothelial cells, respectively. The in vitro LD50 and IC50
Michael J Reese, Deborah W Knapp, Kimberly M Anderson, Julie A Mund, Jamie Case, David R Jones, Rebecca A Packer   +6 more
doaj   +1 more source

Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1-sensitive through NK cell effects

Journal for ImmunoTherapy of Cancer, 2023
Background Tumor intracellular programmed cell death ligand-1 (PDL1) mediates pathologic signals that regulate clinical treatment responses distinctly from surface-expressed PDL1 targeted by αPDL1 immune checkpoint blockade antibodies.Methods We ...
Tyler Curiel, Yilun Deng, Aravind Kancharla, Myrna Garcia, Haiyan Bai, Ryan Michael Reyes, Harshita B Gupta, Alvaro S Padron, Anand V R Kornepati, Jose R Conejo-Garcia, Yiji J Liao, Clare J Murray, Carlos Ontiveros, Suresh J Kari   +13 more
doaj   +1 more source

Long-term management of a cat with nasopharyngeal lymphoma by chlorambucil [PDF]

Open Veterinary Journal, 2021
Background: Lymphoma in the nasal cavity is the most common tumor of cats' upper respiratory tract. However, the effect of single-agent chlorambucil on nasal or nasopharyngeal lymphoma has not been evaluated in cats.
Kaho Takahashi, Takashi Baba, Marin Hirokawa, Masaki Miyajima, Miori Kishimoto, Junpei Kimura, Hirotaka Kondo, Keitaro Ohmori   +7 more
doaj   +1 more source

Chlorambucil-Loaded Graphene-Oxide-Based Nano-Vesicles for Cancer Therapy

Pharmaceutics, 2023
In this study, the authors have designed biocompatible nano-vesicles using graphene oxide (GO) for the release of chlorambucil (CHL) drugs targeting cancerous cells.
Surabhi Kumari, Anuj Nehra, Kshitij Gupta, Anu Puri, Vinay Kumar, Krishna Pal Singh, Mukesh Kumar, Ashutosh Sharma   +7 more
doaj   +1 more source

Nasal Lymphoma with Low Mitotic Index in Three Cats Treated with Chlorambucil and Prednisolone

Veterinary Sciences, 2022
Lymphoma is the most common tumor of the nasal cavity in cats. Commonly used treatment modalities are radiotherapy and chemotherapy, or both. Typical chemotherapy protocols used in cats with nasal lymphoma are COP (cyclophosphamide, vincristine ...
Karen W. L. Ng, Julia A. Beatty, May P. Y. Tse, Antonio Giuliano   +3 more
doaj   +1 more source

Real world risk of infusion reactions and effectiveness of front-line obinutuzumab plus chlorambucil compared with other frontline treatments for chronic lymphocytic leukemia

BMC Cancer, 2022
Background Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in North America. Previous studies have shown improved progression free survival (PFS) and response rates in unfit patients treated with obinutuzumab compared to other ...
Nicole Bourrier, Ivan Landego, Oliver Bucher, Mandy Squires, Erin Streu, Irena Hibbert, Theresa Whiteside, Spencer B. Gibson, Marc Geirnaert, James B. Johnston, David E. Dawe, Versha Banerji   +11 more
doaj   +1 more source

Case Report: Long-Term Survival of a Dog With Chronic Lymphocytic Leukemia Treated With Chlorambucil, Prednisolone, and Imatinib

Frontiers in Veterinary Science, 2022
A 7-year-old castrated male Poodle dog presented with chronic progressive lymphocytosis. Hematologic and peripheral blood smear findings included remarkable lymphocytosis with well-differentiated small lymphocytes. Cytology of bone marrow aspirate showed
Ga-Won Lee, Min-Hee Kang, Jin-Ha Jeon, Doo-Won Song, Woong-Bin Ro, Heyong-Seok Kim, Hee-Myung Park   +6 more
doaj   +1 more source

Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study

Haematologica, 2018
MABLE investigated the efficacy and safety of rituximab plus bendamustine or rituximab plus chlorambucil in fludarabine-ineligible patients with chronic lymphocytic leukemia.
Anne-Sophie Michallet, Melih Aktan, Wolfgang Hiddemann, Osman Ilhan, Peter Johansson, Kamel Laribi, Balkis Meddeb, Carol Moreno, João Raposo, Anna Schuh, Ali Ünal, Tom Widenius, Alf Bernhardt, Kerstin Kellershohn, Dimitri Messeri, Stuart Osborne, Véronique Leblond   +16 more
doaj   +1 more source